JAK阻害剤の現在と将来の状態
Donal P McLornan1, Janet E Pope2, Jason Gotlib3
1Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Lancet (London, England)
|August 29, 2021
まとめ
ジャヌスキナーゼ (JAK) 阻害剤は,JAK-STATシグナル伝達経路をターゲットにすることで,様々な疾患の治療に革命を起こしています. このレビューは,その成功と安全性を要約し,将来の治療開発を探求しています.
科学分野:
- 生物医学
- 薬理学について
- 免疫学
背景:
- ジャヌスキナーゼ (JAK) と信号変換器と転写活性化器 (STAT) の経路は,多くの疾患プロセスにおいて極めて重要です.
- これらの経路を JAK 阻害剤で標的とした治療は,臨床的に有意義であることが示されています.
研究 の 目的:
- 様々なJAK阻害剤の有効性と安全性に関する現在のデータをレビューする.
- JAK阻害剤ベースの治療法の将来の方向性と潜在的な進歩について議論する.
主な方法:
- JAK阻害剤に関する臨床試験と治療データに関する文献レビュー
- 治療の成功と有害事象に関する情報の統合
- 将来の研究と臨床応用に関する仮説分析
主要な成果:
- JAK阻害剤は,骨髄増殖性腫瘍,関節リウマチ,炎症性腸疾患,皮膚疾患の治療において有意な成功を収めている.
- 入手可能なJAK阻害剤の安全性プロファイルは一般的によく特徴付けられ,各剤の特定の副作用が記載されています.
- 基礎研究から臨床応用への迅速な移行が達成されました.
結論:
- JAK阻害剤は,複数の疾患領域における主要な治療的進歩を表しています.
- JAK阻害剤の治療を最適化し,新たな応用を探求するために,継続的な研究が不可欠です.
- JAK-STATのシグナリングを理解することは,次世代の標的治療の開発に不可欠です.
関連する概念動画
01:20The JAK-STAT Signaling Pathway
9.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.6K
02:34Inhibition of Cdk Activity
5.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.1K
01:23Dipeptidyl Peptidase 4 Inhibitors
300
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
300
01:16Therapeutic Drug Monitoring: Overview and Classification
48
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
48
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
251
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
251
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K